🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in France / NCT05916287
Recruiting Not applicable

FAMILY INHERITANCE, GENE-GENE AND GENE-ENVIRONMENT INTERACTIONS IN THE FIELD OF CARDIOVASCULAR AND RENAL DISEASES. Fifth Visit of the STANISLAS Cohort

NCT05916287 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2023-07-13
Last updated
2023-08-15

Condition(s) studied

Cardiovascular DiseasesCohort StudiesGenotypeRisk FactorsNutrition

Investigational drug(s) / intervention(s)

Blood and urine samples →Blood samplesCardiovascular assessmentDietary intakeAnthropometric parametersHemodynamic parametersHemodynamic parametersHemodynamic parametersHemodynamic parametersAssessment of compliance with antihypertensive treatments for treated participantsAmbulatory 24 hours measurment of blood pressure24 hours urinary collectionGeneral questionnairesWomen specific questionnaireWomen specific questionnaireNYHA dyspnea questionnaireAnxiety questionnaireEpworth Sleepiness ScaleA questionnaire on the "perception of the management of cardiovascular risk factors"A questionnaire on eating behaviorsA questionnaire on eating habits to determine consumer profilesA questionnaire on food supplements useSARS-CoV-2 Infection QuestionnaireInstantaneous expired air analysisCapillary sampling

Blood and urine samples: Blood and urine samples

Blood samples: Blood samples

Cardiovascular assessment: Echocardiography, Lung ultrasound, pulse wave velocity, carotid stiffness and thickness, Central and peripheral blood pressure, carotid pulse pressure, abdominal aorta ultrasound, jugular vein ultrasound, liver elastography (Optional).

Dietary intake: Food frequency questionnaires, ''Dutch eating behaviour questionnaire'' and dietary supplement questionnaire

Anthropometric parameters: Measurement of height, weight, abdominal circumference, hip circumference, arm circumference

Hemodynamic parameters: Systolic pressure index measurement

Hemodynamic parameters: Heart rate measurements, blood pressure measurements, orthostatic BP measurements

Hemodynamic parameters: Blood pressure measurements by "unattended BP" monitor over 5 min

Hemodynamic parameters: Electrocardiogram

Assessment of compliance with antihypertensive treatments for treated participants: EVALOBS scale and compliance questionnaire

Ambulatory 24 hours measurment of blood pressure: For the first 100 patients willing to participate

24 hours urinary collection: For the first 100 patients willing to participate. For biobank constitution and measurement of microalbuminuria, creatininuria, osmolarity, natriuresis, kaliuresis, urea, proteinuria and urine dipstick

General questionnaires: Collection of socio-demographic data such as age, level of education, profession, household income, smoking status, physical activity, perception of health, prematurity, height and weight at birth, family and personal history especially cardiovascular (history of stroke, myocardial infarction, heart failure, current pathologies, drugs, tobacco...)

Women specific questionnaire: Women specific questionnaire

Women specific questionnaire: Women specific questionnaire

NYHA dyspnea questionnaire: Determination of NYHA class.

Anxiety questionnaire: Assessment of anxiety

Epworth Sleepiness Scale: sleep quality assessment

A questionnaire on the "perception of the management of cardiovascular risk factors": Patient's evaluation of cardiovascular risk factors by the health system

A questionnaire on eating behaviors: Assessment of eating behaviors

A questionnaire on eating habits to determine consumer profiles: Assessement of eating habit to create a consumer profile

A questionnaire on food supplements use: Evaluation od food supplements intake

SARS-CoV-2 Infection Questionnaire: SARS-CoV-2 Infection Questionnaire

Instantaneous expired air analysis: Carbon monoxyde analysis in expired air

Capillary sampling: Capillary sampling for pollutant analysis (Optional)

Study summary

The Stanislas Cohort is a monocentric familial longitudinal cohort originally comprised of 1006 families consisting of two parents and at least two biological children and deemed healthy, recruited in 1993-1995 at the Centre for Preventive Medicine of Nancy. This cohort was established with the primary objective of investigating gene-gene and gene-environment interactions in the field of cardiovascular diseases. The 5th visit of the STANISLAS Cohort will allow a better evaluation of the cardiovascular ageing of the population and the transition toward cardiovascular or renal diseases in relation with their genetic profile and environment.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * aged over 18 * Person who participated in the Stanislas Cohort * Person affiliated to a social security scheme or beneficiary of such a scheme * Person having received complete information on the organization of the research and having signed an informed consent Exclusion Criteria: * Persons deprived of their liberty by a judicial or administrative decision, persons undergoing psychiatric treatment under Articles L. 3212-1 and L. 3213-1 * Person referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code: * Pregnant woman, parturient or nursing mother * Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice) * Person of full age unable to express consent

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CHRU de Nancy Vandœuvre-lès-Nancy Lorraine Recruiting

More Central Hospital, Nancy, France trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05916287 on ClinicalTrials.gov ↗ ← All trials in France